Saturday - May 17, 2025

LOGIN  |  REGISTER
Cue Biopharma
Cue Biopharma

Enhabit Announces Participation in Upcoming Investor Conferences

February 23, 2023 | Last Trade: US$10.64 0.12 -1.12

DALLAS / Feb 23, 2023 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in two upcoming investor conferences.

Enhabit’s President and Chief Executive Officer Barbara Jacobsmeyer and Chief Financial Officer Crissy Carlisle will participate in fireside chats at the following events:

  • Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York on Wednesday, March 1st, 2023, at 12:30 pm ET
  • Oppenheimer’s 33rd Annual Healthcare Conference (virtual) on Tuesday, March 14th, 2023, at 12:40 pm ET

The fireside chats will be webcast live and available for replay at https://investors.ehab.com under the events and presentations link.

About Enhabit Home Health & Hospice

Enhabit, Inc. is a leading national home health and hospice provider working to expand what’s possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 252 home health locations and 105 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.

Assertio

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page